The COVID-19 pandemic has reshaped global health in ways that extend beyond acute illness. As nations recover, growing evidence points to a concerning long-term consequence: individuals infected with SARS-CoV-2 face a heightened risk of developing diabetes. This post-viral metabolic disruption affects individuals across all age groups, including those without prior glycaemic abnormalities. Cohort studies from the United States, Europe, and Asia consistently demonstrate an increased prevalence of diabetes among COVID-19 survivors. Proposed mechanisms include direct pancreatic injury via ACE2 receptor pathways, immune-mediated β-cell dysfunction, systemic inflammation, and the secondary effects of therapy, stress, and physical inactivity. Despite these findings, post-COVID diabetes remains under-recognized in both clinical practice and public health planning. We contend that this phenomenon represents an impending silent epidemic that could substantially exacerbate the global burden of non-communicable diseases, particularly in low- and middle-income countries with limited screening infrastructure. The absence of targeted surveillance, clinical guidelines, and coordinated research efforts reflects a missed opportunity for early intervention. To prevent a slow-moving public health crisis, post-COVID diabetes must be swiftly integrated into national and global health strategies—through routine metabolic screening in long COVID care, improved data systems, public awareness campaigns, and equitable access to care. Current preventive and policy actions will determine the metabolic health outcomes of future generations.
Lawal et al. (Sat,) studied this question.